Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer

Joseph Cave; Vrushaly Shinglot; Joseph D Butner; Vittorio Cristini; Bulent Ozpolat; George A Calin; Prashant Dogra; Zhihui Wang

doi:10.1109/EMBC40787.2023.10341114

Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer

Joseph Cave, Vrushaly Shinglot, Joseph D Butner, Vittorio Cristini, Bulent Ozpolat, George A Calin, Prashant Dogra, Zhihui Wang

Research output: Contribution to journal › Article › peer-review

Abstract

To improve treatment outcomes in non-small cell lung cancer (NSCLC), it is crucial to identify treatment strategies with the potential to exhibit drug synergism. This can lower the required effective dose, reducing exposure to drugs and associated toxicities, while improving treatment efficacy. In previous studies, drugs targeting the microRNA-155 or PD-L1 have been promising in restraining NSCLC tumor growth. We have developed a mathematical model that simulates the in vivo pharmacokinetics and pharmacodynamics of the novel nanoparticle-delivered anti-microRNA-155 for potential use with standard-of-care drug atezolizumab for NSCLC. Through modeling and simulation, we identified possible drug synergism between the two drugs that holds promise to improve tumor response at reduced drug exposure.Clinical Relevance-Identifying the possibility of drug synergism for an anti-microRNA-155 based nanotherapeutic with standard-of-care immunotherapy to improve lung cancer treatment outcomes.

Original language	English (US)
Pages (from-to)	1-4
Number of pages	4
Journal	Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
Volume	2023
DOIs	https://doi.org/10.1109/EMBC40787.2023.10341114
State	Published - Jul 1 2023

Keywords

Humans
Lung Neoplasms/drug therapy
Carcinoma, Non-Small-Cell Lung/drug therapy
Antibodies, Monoclonal/pharmacology
Treatment Outcome
Immunotherapy
MicroRNAs

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1109/EMBC40787.2023.10341114

Cite this

Cave, J., Shinglot, V., Butner, J. D., Cristini, V., Ozpolat, B., Calin, G. A., Dogra, P., & Wang, Z. (2023). Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2023, 1-4. https://doi.org/10.1109/EMBC40787.2023.10341114

Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer. / Cave, Joseph; Shinglot, Vrushaly; Butner, Joseph D et al.
In: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, Vol. 2023, 01.07.2023, p. 1-4.

Research output: Contribution to journal › Article › peer-review

Cave, J, Shinglot, V, Butner, JD, Cristini, V , Ozpolat, B, Calin, GA, Dogra, P & Wang, Z 2023, 'Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer', Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, vol. 2023, pp. 1-4. https://doi.org/10.1109/EMBC40787.2023.10341114

Cave J, Shinglot V, Butner JD, Cristini V , Ozpolat B, Calin GA et al. Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference. 2023 Jul 1;2023:1-4. doi: 10.1109/EMBC40787.2023.10341114

@article{c0fb9bcd838e47f4ae00d0dd8c3b0cb0,

title = "Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer",

abstract = "To improve treatment outcomes in non-small cell lung cancer (NSCLC), it is crucial to identify treatment strategies with the potential to exhibit drug synergism. This can lower the required effective dose, reducing exposure to drugs and associated toxicities, while improving treatment efficacy. In previous studies, drugs targeting the microRNA-155 or PD-L1 have been promising in restraining NSCLC tumor growth. We have developed a mathematical model that simulates the in vivo pharmacokinetics and pharmacodynamics of the novel nanoparticle-delivered anti-microRNA-155 for potential use with standard-of-care drug atezolizumab for NSCLC. Through modeling and simulation, we identified possible drug synergism between the two drugs that holds promise to improve tumor response at reduced drug exposure.Clinical Relevance-Identifying the possibility of drug synergism for an anti-microRNA-155 based nanotherapeutic with standard-of-care immunotherapy to improve lung cancer treatment outcomes.",

keywords = "Humans, Lung Neoplasms/drug therapy, Carcinoma, Non-Small-Cell Lung/drug therapy, Antibodies, Monoclonal/pharmacology, Treatment Outcome, Immunotherapy, MicroRNAs",

author = "Joseph Cave and Vrushaly Shinglot and Butner, {Joseph D} and Vittorio Cristini and Bulent Ozpolat and Calin, {George A} and Prashant Dogra and Zhihui Wang",

year = "2023",

month = jul,

day = "1",

doi = "10.1109/EMBC40787.2023.10341114",

language = "English (US)",

volume = "2023",

pages = "1--4",

journal = "Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference",

issn = "2375-7477",

publisher = "Institute of Electrical and Electronics Engineers Inc.",

}

TY - JOUR

T1 - Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer

AU - Cave, Joseph

AU - Shinglot, Vrushaly

AU - Butner, Joseph D

AU - Cristini, Vittorio

AU - Ozpolat, Bulent

AU - Calin, George A

AU - Dogra, Prashant

AU - Wang, Zhihui

PY - 2023/7/1

Y1 - 2023/7/1

N2 - To improve treatment outcomes in non-small cell lung cancer (NSCLC), it is crucial to identify treatment strategies with the potential to exhibit drug synergism. This can lower the required effective dose, reducing exposure to drugs and associated toxicities, while improving treatment efficacy. In previous studies, drugs targeting the microRNA-155 or PD-L1 have been promising in restraining NSCLC tumor growth. We have developed a mathematical model that simulates the in vivo pharmacokinetics and pharmacodynamics of the novel nanoparticle-delivered anti-microRNA-155 for potential use with standard-of-care drug atezolizumab for NSCLC. Through modeling and simulation, we identified possible drug synergism between the two drugs that holds promise to improve tumor response at reduced drug exposure.Clinical Relevance-Identifying the possibility of drug synergism for an anti-microRNA-155 based nanotherapeutic with standard-of-care immunotherapy to improve lung cancer treatment outcomes.

AB - To improve treatment outcomes in non-small cell lung cancer (NSCLC), it is crucial to identify treatment strategies with the potential to exhibit drug synergism. This can lower the required effective dose, reducing exposure to drugs and associated toxicities, while improving treatment efficacy. In previous studies, drugs targeting the microRNA-155 or PD-L1 have been promising in restraining NSCLC tumor growth. We have developed a mathematical model that simulates the in vivo pharmacokinetics and pharmacodynamics of the novel nanoparticle-delivered anti-microRNA-155 for potential use with standard-of-care drug atezolizumab for NSCLC. Through modeling and simulation, we identified possible drug synergism between the two drugs that holds promise to improve tumor response at reduced drug exposure.Clinical Relevance-Identifying the possibility of drug synergism for an anti-microRNA-155 based nanotherapeutic with standard-of-care immunotherapy to improve lung cancer treatment outcomes.

KW - Humans

KW - Lung Neoplasms/drug therapy

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - Antibodies, Monoclonal/pharmacology

KW - Treatment Outcome

KW - Immunotherapy

KW - MicroRNAs

UR - http://www.scopus.com/inward/record.url?scp=85179649354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85179649354&partnerID=8YFLogxK

U2 - 10.1109/EMBC40787.2023.10341114

DO - 10.1109/EMBC40787.2023.10341114

M3 - Article

C2 - 38083518

SN - 2375-7477

VL - 2023

SP - 1

EP - 4

JO - Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference

JF - Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference

ER -

Mechanistic modeling of anti-microRNA-155 therapy combinations in lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this